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Reduction in pulmonary function (PF) has been reported in up to 85% of pediatric patients during the ﬁrst
year after hematopoietic stem cell transplantation (HSCT). Our understanding of the etiology for this decrease
in lung function is, however, sparse. The aim of this study was to describe PF during follow-up in a pop-
ulation-based pediatric HSCT cohort and to investigate factors in the transplantation process associated
with PF decline. A retrospective, population-based, single-center study of HSCT patients spanning 2 decades
was performed. Longitudinal changes in PF over time and associations to transplantation-related factors were
investigated using a mixed linear model. One hundred thirty patients were included in the longitudinal
analysis and observed for a median (range) of 3.3 (.2 to 16.8) years, during which 1084 PF tests were per-
formed. Sixty-two percent of the patients experienced a decline in lung function of more than 10% during the
ﬁrst 3 to 9 months after HSCT. The decline in forced expiratory volume in 1 second, forced expiratory volume
in 1 second/forced vital capacity and diffusion capacity of the lung for carbon monoxide were strongly
associated with acute graft-versus-host disease (GvHD). Other factors associated with PF decline were
malignant diagnosis, busulfan-based conditioning, patient and donor age, female donor to male recipient, as
well as chronic GvHD. Mild to moderate decline in PF is frequent and appears associated with acute GvHD and
other parameters that are risk factors for chronic GvHD in children. This indicates that alloreactivity is central
in pathogenesis of the decrease in PF that follows HSCT in children.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION reported in several studies [3,5,6,10-13] primarily demon-
Allogeneic hematopoietic stem cell transplantation
(HSCT) in children has emerged as a curative treatment for
a number ofmalignant and benign hematological diseases, as
well as immunodeﬁciencies and inborn errors of metabo-
lism. Although treatment-related mortality is still consider-
able, improved procedures have resulted in a growing
population of long-term survivors whose life may be affected
by late effects of HSCT. These late effects may be secondary to
toxicity of chemotherapy, radiation, and infections during
the course of the transplantation, as well as graft-versus-host
disease (GvHD).
Pulmonary complications account for considerable
morbidity, bothduring transplantation and later on. Although
severe complications such as bronchiolitis obliterans (BO) are
rare [1], moderate degrees of decreased lung function may
be present in more than one-half of the patients beyond
2 years from HSCT [2-4], most commonly involving the
diffusion capacity of the lung for carbon monoxide (DLCO)
[5-9]. The reduction in forced expiratory volume in 1 second
(FEV1), forced vital capacity (FVC), and FEV1/FVC-ratioedgments on page 1354.
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Although several previous studies have shown a high
prevalence of reduced pulmonary function (PF) after HSCT,
our understanding of the etiology is sparse. Malignant diag-
nosis [8,11,13]; acute [4] and chronic [8,14] GvHD; condi-
tioning with busulfan (BU) [5,12,14] or total body irradiation
(TBI) [8,9]; older [9,10,13], aswell as younger [11] age at HSCT;
female [9,11,15], as well as male [4,11] gender; unrelated
donor [13]; and peripheral blood stem cell source [4] have all
been suggested as possible risk factors. However, variations in
study design, PF parameters, endpoints, and duration of
follow-up have led to divergent conclusions. The aim of the
present study was to describe PF evolution in a national
population-based pediatric HSCT cohort from 1990 to 2010
and associations with transplantation-related factors.
METHODS
Design
The study was designed as a population-based, single-center, longitu-
dinal, and retrospective study using prospectively collected PF and clinical
data from the national Danish pediatric HSCT cohort.
Patient Population
Patients treated with allogeneic HSCT between January 1, 1990 and
December 31, 2010 at an age from 6 to 16 years were candidates for this
study. Children younger than 6 years are seldom able to perform a reliable PF
test, and were, therefore, not included. PF tests were part of a standardized
follow-up program, scheduled to be performedwithin a month before HSCT,Transplantation.
Figure 1. Study population. HSCT indicates hematopoietic stem cell trans-
plantation. PF, pulmonary function.
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no technically sufﬁcient baseline PFwas available. Only patients with at least
1 PF test performed beyond 3 months from HSCT were included in the
longitudinal analysis.
Data Collection
Clinical data were collected from the reports to the Center for Interna-
tional Blood andMarrow Transplantation Research and patient ﬁles. Chronic
GvHD was deﬁned according to the National Institute of Health’s consensus
criteria [16].
Pulmonary Function Tests
FEV1, FVC, maximum midexpiratory ﬂow (MMEF) at 75% to 25% of FVC,
diffusion capacity of the lung for carbon monoxide (DLCO), total lung
capacity (TLC) and residual volume (RV) were measured according to the
recommendations of the European Respiratory Society and American
Thoracic Society [17-19] either at the Department of Clinical Physiology or at
the Department of Pediatric Pulmonary Service at the Copenhagen Univer-
sity Hospital Rigshospitalet, using the Jaeger MasterLab and the Jaeger
Master Screen Pro (Hoechberg, Germany), respectively. Biological quality
control between equipment and locations was regularly performed. TLC and
RV were measured by helium dilution technique. DLCO was measured by
single-breath technique and corrected for hemoglobin (DLCOc) [20] and
alveolar volume (VA) (KCO ¼ DLCO/VA).
PF results were sorted into 4 distinct time intervals relative to day of
HSCT: within 3 months before HSCT, after 3 to 9 months, after 9 to
18 months, and last available measurement beyond 18 months after HSCT.
When more than 1 PF test was available per time interval, the median value
was chosen.
LMS Growth All Age Excel Add-In [21] was used to determine the
percent of predicted value for all spirometric parameters. The reference
equations from Koopman et al. [22] were used to calculate the percent of
predicted value for DLCOc, KCO, TLC, and RV, using extrapolation for patients
older than 18 years of age at their last PF test to avoid abrupt changes due to
differences between reference materials.
Values below 80% of the predicted value for FEV1, FVC, FEV1/FVC, MMEF,
DLCOc, KCO, and TLC were considered abnormal. RV was considered
abnormal and indicative of air trapping when above 120% of the predicted
value. Abnormal FEV1, FEV1/FVC, MMEF, and RV were deﬁned as parameters
of obstructive lung disease, whereas reduced FVC and TLC were interpreted
as indications of restrictive lung disease. DLCOc and KCO were referred as
parameters of diffusion capacity.
Statistics
Simple associations were investigated using Fisher exact test for cate-
gorical and Wilcoxon rank-sum test for continuous data.
Longitudinal changes in PF from baseline were estimated in a mixed
linear model with repeated measures. The explanatory variables, referred to
as HSCT parameters were the year of HSCT, malignant diagnosis, acute and
chronic GvHD, conditioning with BU or TBI, bone marrow or peripheral
blood graft source, donor relation, gender mismatch between donor and
recipient, and age at HSCT. Chronic GvHD was entered as an explanatory
variable from the ﬁrst time interval after chronic GvHD onset. PF valueswere
log transformed for analysis to obtain normally distributed data and back
transformed for presentation.
Associations between changes in PF, HSCT parameters, and time from
transplantation were tested in a univariate mixed model. PF measures were
grouped as obstructive, restrictive, or diffusive (see above). If an HSCT
parameter was found associatedwith a PFmeasure in the univariate analysis
(P < .1), this HSCT parameter was included in the multivariate mixed model
for all PF measures in the same group. Interactions between HSCT param-
eters were tested and included in the analysis if statistically signiﬁcant.
The PROC mixed procedure was used for linear modeling with the
standard variance components for the covariance structure. Statistical
analyses were performed in SAS (version 9.2 SAS Institute Cary, NC).
PF data are presented as mean values or estimated differences (ED) in PF
decrease/increase, with 95% conﬁdence intervals (95% CIs). P values <.05
were considered statistically signiﬁcant.
Ethics
The study was approved by the Danish National Board of Health (J.no.
3-3013-46) and the Danish Data Protection Agency (J.no. 2007-58-0015).
RESULTS
Patient Characteristics
During the period 1990 to 2010, a total of 185 patients,
ages 6 to 16, underwent HSCT in Denmark. Of those, weidentiﬁed 154 patients who had a technically sufﬁcient
baseline PF test (Figure 1). Characteristics of the study pop-
ulation are presented in Table 1 and did not differ signiﬁ-
cantly from the characteristics of the 31 patients who were
excluded. Twenty-one of the excluded patients died during
follow-up, however, and the group that survived was signif-
icantly younger at time of HSCT than the patients included in
this study (median age, 7.6 versus 10.4 years; P ¼ .014).
Twenty-four patients (15.5%) were lost to second follow-
up. These patients were no different than the rest of the
study population as to age, diagnosis, donor match, graft
type, conditioning regimen, and acute GvHD, but had
a higher mortality, as 92% (n ¼ 22) died at median (range)
125.5 (2 to 449) days from HSCT. In 2 cases, pulmonary
complications were the primary cause of death. In compar-
ison, 21% (n ¼ 27) of patients in the longitudinal cohort died
(P < .001), 4 of those due to noninfectious pulmonary
complications. In linewith this, signiﬁcantlymore patients in
our longitudinal cohort survived to reveal chronic GvHD
(28.9 versus 8.7%, P ¼ .042).
One hundred thirty patients were included in the longi-
tudinal analysis. Five patients had BO veriﬁed by open lung
biopsy. Another 10 patients had indications of obstructive
lung disease during follow-up evidenced by FEV1<75% and
FEV1/FVC ratio below .7. The NIH criteria for BO [16] were not
evaluable in this cohort, as chest high-resolution computed
tomography (HRCT) or RV measurement were missing from
more than one-half of the evaluations.Baseline Pulmonary Function
Seventy-ﬁve percent (n ¼ 116) of the patients had at least
1 abnormal lung function parameter before HSCT, primarily
presented as abnormal FEV1, FVC, RV, and/or diffusion
capacity (Table 2). We found no signiﬁcant differences in age,
sex, or diagnosis between patients with abnormal versus
normal PF at time of HSCT.Pulmonary Function during Follow-up
A total of 1084 sets of PFs were collected with a median
(range) total observation period of 3.3 (.2 to 16.8) years. The
median (range) number of evaluable PF tests per patient was
5 (1 to 85). PF tests included in the last available
Table 1
Characteristics of the Study Population (n ¼ 154)
Characteristic n (%)
Female/male patient ratio 65 (42.2)/89 (57.8)
Sex mismatch between donor and recipient
Male to female 34 (22.1)
Female to male 37 (24.0)
Age at HSCT, median (range), yr 10.4 (6 to 6)
Diagnosis
ALL 71 (46.1)
AML 18 (11.0)
Other malignant diseases 25 (16.2)
Benign hematological diseases 33 (21.4)
Immunodeﬁciencies 2 (1.3)
Other diseases 6 (3.9)
Donor age, median (range), yr 29.0 (0 to 58)
Donor type
HLA-identical sibling donor 57 (37.0)
Other donor 97 (63.0)
Graft type*
Bone marrow 143 (92.9)
Peripheral blood 10 (6.5)
Umbilical cord 4 (2.6)
CMV status
Donor positive 78 (50.6)
Recipient positive 91 (59.1)
Mismatch between donor and recipient 46 (29.9)
Chemotherapy
BU (i.v., n ¼ 32) 52 (33.8)
TBI (>1000 cGy n ¼ 84) 88 (57.1)
CY 128 (83.1)
Etoposide 33 (21.4)
Fludarabin 4 (2.6)
Conditioning regimensy
BUþCY 52 (33.8)
TBIþCY 62 (40.3)
TBIþetoposide 26 (16.9)
Others 16 (10.4)
Acute GvHD 95 (61.7)
Grade 1 to 2 76 (49.4)
Grade 3 to 4 19 (12.3)
Chronic GvHD (ﬁrst 18 mo) 39 (25.3)
HSCT indicates hematopoietic stem cell transplantation; ALL, acute
lymphoblastic leukemia; AML, acute myelomonocytic leukemia; HLA,
human leukocyte antigen; BU, busulfan; TBI, total body irradiation; CY,
cyclophosphamide; GvHD, graft-versus-host disease; CMV, cytomegalo-
virus.
Data presented are n (%) unless otherwise indicated.
* One patient received stem cells from both bone marrow and peripheral
blood and 2 patients from both bone marrow and umbilical cord.
y Two patients received TBIþBUþCY.
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at median (range) 5.0 (1.5 to 16.8) years from HSCT.
The most remarkable decrease in PF was seen from
baseline and 3 to 9 months after HSCT (Figure 2). Sixty-two
percent of the patients experienced a decrease of more
than 10% in 1 or more of FEV1, FEV1/FVC, MMEF, FVC, TLC,
DLCOc, or KCO, or an equivalent increase in RV during this
period.
Accordingly, mean values of FEV1, FVC, and TLC decreased
signiﬁcantly from baseline and during the ﬁrst 3 to 9 months
after HSCT (Figure 2). Whereas mean FVC slightly improved,
there were no signiﬁcant longitudinal changes in FEV1 and
TLC during the subsequent periods. Mean DLCOc was
substantially reduced and consistently abnormal during the
entire follow-up. However, the KCO actually increased
signiﬁcantly from 3 to 9 months to the last available
measurement after HSCT (P < .0001). Mean FEV1/FVC and
MMEF remained unchanged during follow-up.
Two-thirds of the patients (n ¼ 100) had their last avail-
able PF measurement performed beyond 3 years from HSCT.In a subanalysis, the pattern of PF was the same in these
patients as in the cohort as a whole.
Associations between PF Decrease and HSCT Parameters
Acute GvHD debuted at median (range) 14 (6 to 50) days
from HSCT and was strongly associated with a clinically
signiﬁcant decrease in FEV1, as well as FEV1/FVC, FVC, and
DLCOc (Table 3). For FEV1, the inﬂuence of acute GvHD was
more pronounced in patients who did not have an HLA-
identical sibling donor. Chronic GvHD was related with
a decrease in FEV1 and FVC, and we found a tendency toward
an associationwith reduction in FEV1/FVC as well, although it
did not reach statistical signiﬁcance in the multivariate
model.
Malignant diagnosis was related to a decrease in FEV1,
FVC, TLC, and DLCOc (Table 3) as well as KCO (ED, 13.6; 95%
CI, 20.0 to 6.7; P ¼ .003).
One-third of our patients were conditioned with BU in
combination with cyclophosphamide (CY), of whom 61.5%
(n ¼ 32) received BU intravenously (Table 1). BUþCY
conditioning was found correlated to decreases in FEV1,
FEV1/FVC, and DLCOc. No difference in PF reduction was
observed between patients who received intravenous versus
oral BU. The standard dose of CY was 120 mg/kg/day,
although in some cases (n ¼ 23) of benign hematological or
metabolic diseases, 200 mg/kg/day was administered.
TBI was given in combination with CY or etoposide
(Table 1). The dose of TBI was 1200 cGy in all but 4 cases. The
univariate analysis indicated a correlation between TBI and
a decrease in FVC (ED, 7.1; 95% CI, 13.2 to 1.3; P ¼ .016)
and TLC (ED, 5.6; 95% CI, 11.9 to .3; P ¼ .062). However,
this could not be conﬁrmed in the multivariate model
(Table 3).
Male recipients with female donors showed a larger
decrease in FEV1/FVC and DLCOc than patients with other
donor-recipient combinations. A cytomegalovirus (CMV)
status mismatch with a CMV-positive recipient receiving
stem cells from a CMV-negative donor was correlated with
a decrease in FEV1 and FVC.
The year of HSCT, graft source (bone marrow versus
peripheral blood), HSCTs with male donors to female recip-
ients, and CMV-positive donors to CMV-negative recipients
were not found independently associated with PF decline.
DISCUSSION
Lung Function and Inﬂammatory Reactions during HSCT
This study demonstrates that deterioration in PF among
pediatric HSCT patients is frequent and is associated with
acute as well as chronic GvHD.
To our knowledge, only 1 pediatric study has described
a similar relation between PF and acute GvHD [4], reporting
an increased risk of abnormal FVC in patients with acute
GvHD. In contrast, a retrospective study from Kaya et al. [5]
found higher mean FEV1 and FVC in acute GvHD patients
3 months after HSCT. The differences in PF values compared
with non-GvHD patients and baseline were not reported,
and this hampers comparison with our results. Chronic
GvHD has previously been associated with low FEV1, FVC,
FEV1/FVC, MMEF, and high RV 2 years after HSCT [14], as
well as abnormal FEV1/FVC ratio (<.8) beyond 5 years from
HSCT [8].
Our ﬁndings suggest a central role of alloreactivity in the
pathogenesis of the lung involvement that follows HSCT in
the majority of children. In line with this, a number of other
factors previously reported to be risk factors for chronic
Table 2
Number of Patients with Normal or Reduced PF at Various Time Points Relative to HSCT*
FEV1 FEV1/FVC MMEF RV FVC TLC DLCOc KCO Not Evaluable because
of Death (cum)
Time Point Not
Yet Reached, n
Before SCT
Normal 114y (74) 148 (97) 29 (45) 36 (43) 107 (70) 94 (97) 70 (59) 60 (49)
Abnormal 40 (26) 5 (3) 35 (55) 48 (57) 46 (30) 3 (3) 48 (41) 63 (51)
3 to 9 mo
Normal 62 (55) 105 (94) 27 (55) 15 (28) 53 (47) 54 (86) 20 (26) 22 (32) 9
Abnormal 50 (45) 7 (6) 22 (45) 38 (72) 60 (53) 9 (14) 57 (74) 46 (68)
9 to 18 mo
Normal 57 (56) 98 (96) 26 (52) 8 (24) 55 (54) 42 (89) 20 (32) 26 (46) 22
Abnormal 44 (43) 4 (4) 24 (48) 26 (76) 47 (46) 5 (11) 43 (68) 31 (54)
Last available >18 mo
Normal 66 (66) 96 (96) 57 (66) 10 (28) 66 (66) 65 (88) 23 (29) 61 (73) 36 2
Abnormal 34 (34) 4 (4) 29 (34) 26 (72) 34 (34) 9 (12) 55 (71) 22 (27)
PF indicates pulmonary function; HSCT, hematopoietic stem cell transplantation; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; MMEF,
maximummidexpiratory ﬂow; RV, residual volume; TLC, total lung capacity; DLCOc, diffusion capacity of the lung for carbonmonoxide corrected for hemoglobin
value; KCO, (¼DLCO/VA), volume-corrected diffusion capacity.
Data presented are n (%) unless otherwise indicated.
* Abnormal values are deﬁned as below 80% of predicted values for FEV1, FEV1/FVC, MMEF, RV, TLC, DLCOc, and KCOand above 120% for RV.
y One patient had evaluable FEV1 but no FVC.
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including malignant diagnosis, female donor to male recip-
ient, and increased patient and donor age. Peripheral blood
graft has been described as a risk factor for chronic GvHD
[24] and reduced PF [4]. As 92% of our cohort received bone
marrow grafts, these relations were not powered to be
investigated in our cohort.
Importantly, only a minor part of our cohort met the
criteria for BO, which is considered a manifestation of
chronic pulmonary GvHD [16]. This may suggest that the
post-HSCT decline in PF represents a continuum of lung
impairment caused by increasing degrees of lung-directed
alloreactivity, where BO constitutes the extreme presenta-
tion. In the less severe form, this is manifested as the
unspeciﬁc and moderate deterioration in PF, experienced by
the majority of patients.
It is likely that the general inﬂammation resulting from
acute GvHD affects the lungs, rendering them more vulner-
able to later insults, including infections. The impact of
infections and previous chemotherapy on the lung tissue
may explain why malignant diagnosis is found associated
with decrease in PF. As reported in the present study, Wier-
inga et al. [11] have previously described a larger decrease in
diffusion capacity in patients with malignant diagnosis
beyond 3 months from HSCT. In line with our ﬁndings, Quigg
et al. [12] demonstrate lower mean values of FEV1, FVC, and
TLC 1 year after HSCT in a cohort of pediatric HSCT patients
with refractory, malignant disease comparedwith patients in
complete remission or with nonmalignant disease. These
studies and others [8,13] indicate that former intensive
chemotherapy may render the lung tissue more vulnerable
to HSCT-related pulmonary insults caused by infections,
acute GvHD, and toxicity, in turn inducing a stronger
inﬂammatory response.
Increased toxicity and resulting inﬂammation may
explain why BU conditioning was found related to signs of
obstructive lung involvement. One pediatric study has
described the same relation 1 to 2 years after HSCT [14]. Kaya
et al. found BU-conditioned patients to have a lower mean
FEV1 3 months after HSCT, and several large studies on adult
patients have described BU as a risk factor for obstructive
lung disease [25-27].
However, as a demonstration of the continued discrep-
ancies in this ﬁeld, Leung et al. [9] described TBI conditioningto be predictive of abnormal (deﬁned as <85% of predicted)
FEV1/FVC, TLC, and DLCO.
Only a few of the previously mentioned studies [4,11,14]
applied, as we did, the percentage decrease in mean PF
compared with baseline as the primary endpoint. Others
have studied risk factors for abnormal post-HSCT PF tests
[2,4,7-9] or differences in mean values at different points of
follow-up [4,5,12-15]. In combination with differences in
follow-up time, study design, population size, and study
period, this may partly explain the divergent results
described in the above.Types of Lung Involvement after HSCT
A large proportion of patients in our and preceding
studies [2-5] have already shown evidence of lung impair-
ment before HSCT. A decline in PF took place during the ﬁrst
3 to 9 months after HSCT, after which PF appeared to stabi-
lize. As previously reported [5,11-13], the decrease in FEV1
and FVC was discrete and subsequently slightly improved,
whereas a more pronounced and permanent decrease was
seen in DLCOc [2,3,11].
A reduction in TLC combined with a stable, normal FEV1/
FVC supports the notion of a primarily restrictive volume
reduction [2,11,15,28]. However, the reported increase in RV
[4,12,28] indicates an obstructive component that might be
“hidden” by a simultaneous decrease in FVC and FEV1
keeping the FEV1/FVC ratio unchanged.
Diffusion deﬁcits are reportedly the most frequent long-
term PF defect after pediatric HSCT, being present in 35% to
58% of survivors beyond 3 years [5-9]. In our study, about
two-thirds of patients had abnormal values of DLCOc at
a median of 5 years after HSCT. However, when the diffusion
capacity was adjusted for alveolar volume (KCO), the decrease
was only transient, and mean KCO subsequently increased to
values above baseline. A similar pattern was described by
Quigg et al. [12]. As alveolar volume (wTLC) stayed
unchanged beyond 3 to 9 months after HSCT, whereas DLCOc
slightly increased, the improved KCO may primarily reﬂect
improved gas exchange across the capillary-alveolar
membrane or improved pulmonary capillary circulation.
Studies involving combined diffusion capacity for nitrogen
oxide and CO might provide further knowledge on this
physiological mechanism [29].
Figure 2. Lung function development in a pediatric HSCT cohort. Circles represent individual patients. Horizontal lines represent population means with 95%
conﬁdence intervals. *Compared to baseline values. **Comparing post-HSCT values. HSCT indicates hematopoietic stem cell transplantation; m, months from HSCT;
FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; MMEF, maximum midexpiratory ﬂow; RV, residual volume; TLC, total lung capacity; DLCOc,
diffusion capacity of the lung for carbon monoxide corrected for hemoglobin values; KCO, (¼DLCO/VA) volume-corrected diffusion capacity.
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Table 3
Multivariate Analysis of Associations between Decrease in PF and HSCT
Parameters
HSCT Parameter PFT
Parameter
Estimate of
Difference*
95% CI P
Value
Patient age, per 5 yrs
of age
FEV1 8.1 14.0 to 1.7 .014
FEV1/FVC 3.6 6.5 to .5 .024
FVC 3.4 8.2 to 1.7 .19
TLC 6.9 11.9 to 1.5 .013
DLCOc 5.8 11.3 to .04 .049
Donor age, per 5 yrs
of age
FEV1 2.7 5.1 to .2 .033
FEV1/FVC .8 1.9 to .4 .18
FVC 1.9 2.9 to .9 .0004
TLC 1.6 2.6 to .6 .002
DLCOc 1.3 2.4 to .2 .026
Sex FEV1 7.8 18.1 to 1.7 .11
Female donors to
male recipients
versus others
FEV1/FVC 7.9 12.7 to 3.4 .0006
FVC - - -
TLC - - -
DLCOc 12.3 21.4 to 3.9 .0041
Diagnosis FEV1 13.6 20.4 to 6.2 .0006
Malignant disease FEV1/FVC 2.0 5.7 to 1.7 .28
FVC 10.9 16.9 to 4.4 .0016
TLC 8.8 14.9 to 2.2 .011
DLCOc 13.9 20.3 to 6.9 .0003
Donor FEV1 4.8y 11.2 to 23.6 .58
HLA identical sibling FEV1/FVC 1.7 8.1 to 5.1 .61
FVC - - -
TLC - - -
DLCOc - - -
Conditioning FEV1 - - -
Total body irradiation FEV1/FVC - - -
FVC 1.4 7.9 to 5.6 .69
TLC 4.7 11.9 to 2.1 .17
DLCOc - - -
Busulfan FEV1 10.6 19.6 to 2.3 .012
FEV1/FVC 4.5 8.4 to .8 .019
FVC - - -
TLC - - -
DLCOc 17.0 26.6 to 8.2 .0002
CMV status FEV1 10.7 21.2 to 1.2 .028
Negative donor to
positive recipient
FEV1/FVC 3.7 8.2 to .6 .093
FVC 7.6 15.4 to .3 .042
TLC 1.2 5.8 to 7.6 .73
DLCOc - - -
Acute GvHD FEV1 19.4z 33.1 to 6.8 .002
FEV1/FVC 4.6 8.8 to .5 .026
FVC 4.6 11.8 to 2.2 .19
TLC 2.4 9.9 to 4.7 .52
DLCOc 8.3 16.3 to .9 .029
Chronic GvHD FEV1 16.3 30.6 to 3.6 .013
FEV1/FVC 5.1 10.9 to .3 .065
FVC 13.8 24.5 to 4.1 .0067
TLC 2.7 11.4 to 5.4 .49
DLCOc - - -
Yr of HSCT FEV1 .4 .4 to 1.1 .35
FEV1/FVC .04 .3 to .4 .82
FVC .1 .4 to .8 .54
TLC .5 1.1 to .2 .15
DLCOc .4 .4 to 1.1 .32
PF indicates pulmonary function; FEV1, forced expiratory volume in
1 second; FVC, forced vital capacity; TLC, total lung capacity; DLCOc, diffusion
capacity of the lung for carbon monoxide corrected for hemoglobin value;
HLA, human leukocyte antigen; CMV, cytomegalovirus; GvHD, graft-versus-
host disease; HSCT, hematopoietic stem cell transplantation.
* Estimate of difference in PF % decrease between holders of the HSCT
parameter compared to others.
y Because of the interaction between HLA-identical sibling donor and
acute GvHD regarding FEV1, the estimate relates only to patients with acute
GvHD. In patients without acute GvHD, the difference in estimated FEV1-
decrease between patients with HLA-identical sibling donors and patients
with other donors was 12.1.
z The estimate relates to patients with other donors than HLA-identical
siblings. For patients with HLA-identical sibling donors, the difference in
estimated FEV1 decrease between patients with/without acute GvHD
was 2.4.
H.H. Uhlving et al. / Biol Blood Marrow Transplant 19 (2013) 1348e1354 1353The major strengths of this study are the size and the
population-based design, with a close and relatively uniform
follow-up of all patients, as well as the detailed clinical data
available.
The study has limitations according to the design.
Although PF tests were scheduled to take place at regular
intervals, a complete program was not achieved in all
patients. A selection bias is possible, as less affected patients
were likely to skip regular follow-up at an earlier stage.
Moreover, as PF tests require some degree of patient coop-
eration, the youngest children and the patients with the
most severe disease may not be able to cooperate. This is
reﬂected by the high mortality and relatively young age of
the patients who were excluded from this study. A poor
clinical status may also explain why 24 patients were lost to
second follow-up, as 92% of these patients died within
18 months from HSCT.
Improvements in supportive care including more effec-
tive antifungal therapy and change of BU administration
from oral to intravenous formulation, as well as changes in
referral practice during the 20-year study period, may have
inﬂuenced the results of this study. When correcting for
diagnosis, conditioning regimen, GvHD, and other factors,
however, the year of HSCT was not found independently
associated with PF decrease.
The signiﬁcance of appropriate reference values of PF is
obvious. For TLC, RV, and diffusion capacity, no continuous
reference material exists, and adult reference values [30]
predict higher results for an 18-year-old than the pediatric
reference values used in this study [22]. To avoid an artiﬁcial
decrease in relative PF test values for persons passing their
18th birthday, we extrapolated the pediatric reference
values. This could result in a slight overestimation of PF
results in the young adults, and a slight underestimation in
the older participants. The oldest participant in this study
was 27 years old at last follow-up.
Our results on RV and TLC should be interpreted with
caution, as the measurements are derived from assessment
with helium dilution and not from body plethysmography,
which is considered the gold standard technique. Thus, in
patients with normal lung function, helium dilution has been
known to slightly overestimate the TLC, whereas the oppo-
site is true for patients with areas of the lung that are poorly
or nonhomogeneously ventilated because of severe
obstruction [31].
Conclusions and Future Perspectives
In this study, we describe a relationship between decrease
in PF and acute and chronic GvHD, which deserves further
exploration in a prospective study. This ﬁnding suggests
a potential importance of alloreactivity as a pathogenic factor
in the majority of pediatric HSCT patients. The deterioration
in PF may represent a continuum of lung pathology induced
by alloreactivity, which at one end leads to a mild to
moderate decline in PF, and in its extreme presentation,
becomes fulminate BO. Accordingly, recognition of early
signs of pulmonary impairment might inﬂuence the clini-
cian’s decision regarding the dosage of immunosupressive
treatment; hence, possibly reducing the occurrence of BO. A
prospective longitudinal study is currently being performed
at our center, testing the signiﬁcance of frequent standard PF
measurements as well as the promising method of multiple
breath washout [32,33] for the early detection of small
airways disease after HSCT in children.
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